$89.95
+0.75
(+0.84%)▲
Insights on Irhythm Technologies, Inc.
Revenue is up for the last 3 quarters, 111.43M → 124.60M (in $), with an average increase of 5.3% per quarter
Netprofit is down for the last 2 quarters, -18.48M → -27.11M (in $), with an average decrease of 46.7% per quarter
In the last 1 year, Stryker Corporation has given 22.5% return, outperforming this stock by 42.1%
In the last 3 years, Boston Scientific Corp. has given 24.3% return, outperforming this stock by 75.0%
1.83%
Downside
Day's Volatility :2.84%
Upside
1.02%
21.91%
Downside
52 Weeks Volatility :49.91%
Upside
35.86%
Period | Irhythm Technologies, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -10.41% | -1.3% | 0.0% |
6 Months | -15.22% | 1.2% | 0.0% |
1 Year | -13.19% | -5.7% | -6.5% |
3 Years | -50.66% | 17.1% | -6.5% |
Market Capitalization | 2.7B |
Book Value | $7.18 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -3.44 |
PEG Ratio | 0.0 |
Wall Street Target Price | 113.3 |
Profit Margin | -22.19% |
Operating Margin TTM | -19.75% |
Return On Assets TTM | -13.54% |
Return On Equity TTM | -45.71% |
Revenue TTM | 472.8M |
Revenue Per Share TTM | 15.56 |
Quarterly Revenue Growth YOY | 20.0% |
Gross Profit TTM | 281.6M |
EBITDA | -81.8M |
Diluted Eps TTM | -3.44 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.38 |
EPS Estimate Next Year | -2.28 |
EPS Estimate Current Quarter | -0.66 |
EPS Estimate Next Quarter | -0.57 |
What analysts predicted
Upside of 25.96%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 98.5M | ↑ 53.75% |
Net Income | -29.4M | ↑ 40.75% |
Net Profit Margin | -29.87% | ↑ 2.75% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 147.3M | ↑ 49.52% |
Net Income | -48.3M | ↑ 64.11% |
Net Profit Margin | -32.78% | ↓ 2.91% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 214.6M | ↑ 45.66% |
Net Income | -54.6M | ↑ 13.02% |
Net Profit Margin | -25.43% | ↑ 7.35% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 265.2M | ↑ 23.59% |
Net Income | -43.8M | ↓ 19.68% |
Net Profit Margin | -16.53% | ↑ 8.9% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 322.8M | ↑ 21.74% |
Net Income | -101.4M | ↑ 131.26% |
Net Profit Margin | -31.4% | ↓ 14.87% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 410.9M | ↑ 27.29% |
Net Income | -116.2M | ↑ 14.6% |
Net Profit Margin | -28.27% | ↑ 3.13% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 102.1M | ↑ 10.47% |
Net Income | -23.9M | ↓ 52.78% |
Net Profit Margin | -23.42% | ↑ 31.36% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 103.9M | ↑ 1.79% |
Net Income | -21.5M | ↓ 10.24% |
Net Profit Margin | -20.65% | ↑ 2.77% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 112.6M | ↑ 8.42% |
Net Income | -20.2M | ↓ 5.84% |
Net Profit Margin | -17.94% | ↑ 2.71% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 111.4M | ↓ 1.05% |
Net Income | -39.1M | ↑ 93.63% |
Net Profit Margin | -35.1% | ↓ 17.16% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 124.1M | ↑ 11.39% |
Net Income | -18.5M | ↓ 52.74% |
Net Profit Margin | -14.89% | ↑ 20.21% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 124.6M | ↑ 0.38% |
Net Income | -27.1M | ↑ 46.72% |
Net Profit Margin | -21.76% | ↓ 6.87% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 133.1M | ↓ 3.64% |
Total Liabilities | 53.6M | ↑ 17.49% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 119.7M | ↓ 10.08% |
Total Liabilities | 65.3M | ↑ 21.87% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 306.2M | ↑ 155.79% |
Total Liabilities | 170.8M | ↑ 161.61% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 511.7M | ↑ 67.12% |
Total Liabilities | 170.1M | ↓ 0.4% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 463.0M | ↓ 9.53% |
Total Liabilities | 183.5M | ↑ 7.83% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 448.2M | ↓ 3.18% |
Total Liabilities | 208.4M | ↑ 13.6% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 435.7M | ↑ 1.63% |
Total Liabilities | 191.0M | ↑ 3.9% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 440.4M | ↑ 1.08% |
Total Liabilities | 201.2M | ↑ 5.3% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 448.2M | ↑ 1.78% |
Total Liabilities | 208.4M | ↑ 3.6% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 421.7M | ↓ 5.92% |
Total Liabilities | 199.9M | ↓ 4.1% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 429.5M | ↑ 1.85% |
Total Liabilities | 205.6M | ↑ 2.87% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 439.8M | ↑ 2.39% |
Total Liabilities | 220.0M | ↑ 6.99% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -14.9M | ↓ 10.45% |
Investing Cash Flow | -34.7M | ↓ 49.12% |
Financing Cash Flow | 6.5M | ↓ 94.13% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -29.1M | ↑ 94.94% |
Investing Cash Flow | 34.1M | ↓ 198.37% |
Financing Cash Flow | 6.3M | ↓ 3.51% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -21.9M | ↓ 24.79% |
Investing Cash Flow | -89.3M | ↓ 361.67% |
Financing Cash Flow | 111.6M | ↑ 1670.2% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -13.8M | ↓ 37.07% |
Investing Cash Flow | -132.4M | ↑ 48.3% |
Financing Cash Flow | 214.3M | ↑ 92.08% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -37.8M | ↑ 174.39% |
Investing Cash Flow | 105.3M | ↓ 179.51% |
Financing Cash Flow | -28.6M | ↓ 113.33% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -23.0M | ↓ 39.05% |
Investing Cash Flow | -52.4M | ↓ 149.81% |
Financing Cash Flow | 26.7M | ↓ 193.49% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -372.0K | ↓ 99.04% |
Investing Cash Flow | -431.0K | ↓ 94.95% |
Financing Cash Flow | 7.3M | ↓ 50.33% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.7M | ↓ 1086.29% |
Investing Cash Flow | -35.4M | ↑ 8104.64% |
Financing Cash Flow | 1.7M | ↓ 77.14% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 12.6M | ↑ 242.76% |
Investing Cash Flow | -8.1M | ↓ 77.05% |
Financing Cash Flow | 3.1M | ↑ 89.41% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -30.8M | ↓ 344.54% |
Investing Cash Flow | 3.8M | ↓ 147.08% |
Financing Cash Flow | 905.0K | ↓ 71.25% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.6M | ↓ 85.13% |
Investing Cash Flow | 9.0M | ↑ 135.84% |
Financing Cash Flow | 4.4M | ↑ 384.09% |
Sell
Neutral
Buy
Irhythm Technologies, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Irhythm Technologies, Inc. | 10.15% | -15.22% | -13.19% | -50.66% | 20.43% |
![]() Stryker Corporation | 7.57% | 7.13% | 25.17% | 24.29% | 72.88% |
![]() Dexcom, Inc. | 22.96% | -6.45% | 0.05% | 34.03% | 264.69% |
![]() Boston Scientific Corp. | 6.31% | 9.22% | 23.6% | 63.15% | 53.72% |
![]() Abbott Laboratories | 10.4% | 1.08% | -0.5% | -2.8% | 46.69% |
![]() Medtronic Plc | 8.95% | -4.47% | 1.52% | -29.74% | -17.1% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Irhythm Technologies, Inc. | NA | NA | 0.0 | -3.38 | -0.46 | -0.14 | 0.0 | 7.18 |
![]() Stryker Corporation | 43.5 | 43.5 | 2.85 | 10.41 | 0.15 | 0.07 | 0.01 | 47.13 |
![]() Dexcom, Inc. | 124.12 | 124.12 | 11.34 | 1.42 | 0.18 | 0.06 | 0.0 | 5.87 |
![]() Boston Scientific Corp. | 67.84 | 67.84 | 2.53 | 2.01 | 0.07 | 0.04 | 0.02 | 12.89 |
![]() Abbott Laboratories | 34.99 | 34.99 | 18.76 | 4.44 | 0.14 | 0.06 | 0.02 | 21.59 |
![]() Medtronic Plc | 25.64 | 25.64 | 3.04 | 5.28 | 0.08 | 0.04 | 0.03 | 38.69 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Irhythm Technologies, Inc. | Buy | $2.7B | 20.43% | NA | -22.19% |
![]() Stryker Corporation | Buy | $111.6B | 72.88% | 43.5 | 13.0% |
![]() Dexcom, Inc. | Buy | $43.1B | 264.69% | 124.12 | 11.08% |
![]() Boston Scientific Corp. | Buy | $81.5B | 53.72% | 67.84 | 8.93% |
![]() Abbott Laboratories | Buy | $178.6B | 46.69% | 34.99 | 12.92% |
![]() Medtronic Plc | Buy | $105.1B | -17.1% | 25.64 | 12.84% |
Vanguard Group Inc
Capital Research Global Investors
Sands Capital Management, LLC
BlackRock Inc
Artisan Partners Limited Partnership
AllianceBernstein L.P.
Irhythm Technologies, Inc.’s price-to-earnings ratio stands at None
Read Moreirhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ecg, monitoring for patients at risk for arrhythmias. we have created a unique platform, zio by irhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.
Organization | Irhythm Technologies, Inc. |
Employees | 1793 |
CEO | Mr. Quentin S. Blackford |
Industry | Health Technology |